OP-C14

Solid Lipid Nanoparticles of Lopinavir for Lymphatic Targeting

Chanchal Deep Kaur

Shri Rawatpura Sarkar Institute of Pharmacy, Kumhari, Durg. CG, India

Corresponding author email: dr.chanchaldeep@gmail.com

[Received 15 January 2016; accepted 29 January 2016]

Abstract. Lymphatic disorders are vital problem in front of drug delivery cargoes because of their specific tissues and drainage system. Lymphatic disorders need an advanced delivery system which can reach there and deliver the drug. Novel lipid-based nanoformulations, such as solid lipid nanoparticles and nanostructured lipid carriers, have unique characteristics that make them promising candidates for lymphatic delivery. In present study, surface modified Lopinavir loaded solid lipid nanoparticles (MA-Lo-SLN) were formulated by hot homogenization process. The formulated SLN (MA-Lo-SLN) was found to exhibit a mean particle size of 220 nm (polydispersity index, PDI<0.27) and zeta potential was found to be between -25mV to -28mV. Particles were characterized using differential scanning calorimetry (DSC), XRD and SEM studies to confirm their structural morphology and the homogeneous distribution of drug within the lipid matrix. In vitro release studies at pH 6.8 phosphate buffer (PBS) showed a slow but sustained release profile of drug. Fluorescence microscopy was done to confirm the lymphatic targeting. The study results confirm that the MA-Lo-SLN exhibits desired characteristic for targeting lymphatic system.

Keywords: Lymphatic system, Solid Lipid Nanoparticles, Lopinavir, Surface Engineered, particle size.